A phase II study of Nivolumab re-challenge therapy in patients with advanced non-small cell lung cancer who responded to prior PD-1/L1 inhibitors (WJOG9616L) (UMIN-CTR) - Oct 4, 2026 - P2 | N=60 | Completed | Sponsor: West Japan Oncology Group | Phase classification: P=N/A ➔ P2
Phase classification • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|